| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:PR-104 CAS:851627-62-8 Purity:>=97% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Products Intro: |
Product Name:PR104 CAS:851627-62-8 Purity:95% -98%HPLC Package:1GR;10GR;50GR;100GR;250GR;500GR;1KG;5KG;10KG;100KG
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:PR-104 CAS:851627-62-8 Package:2mg/RMB 3420;25mg/RMB 10600;50mg/RMB 13800
|
PR104 manufacturers
- PR-104
-
- $2500.00
-
2026-04-22
- CAS:851627-62-8
- Purity:
- Supply Ability: 10g
|
| Product Name: | PR104 | | Synonyms: | PR-104/104A;PR104;2-((2-Bromoethyl)(2,4-dinitro-6-((2-(phosphonooxy)ethyl)carbamoyl)phenyl)amino)ethyl methanesulfonate;GZSOKPMDWVRVMG-UHFFFAOYSA-N;2-[N-(2-bromoethyl)-2,4-dinitro-6-(2-phosphonooxyethylcarbamoyl)anilino]ethyl methanesulfonate;PR 104;PR104;Benzamide, 2-[(2-bromoethyl)[2-[(methylsulfonyl)oxy]ethyl]amino]-3,5-dinitro-N-[2-(phosphonooxy)ethyl]- | | CAS: | 851627-62-8 | | MF: | C14H20BrN4O12PS | | MW: | 579.27 | | EINECS: | | | Product Categories: | | | Mol File: | 851627-62-8.mol |  |
| | PR104 Chemical Properties |
| storage temp. | 4°C, away from moisture and light | | form | Solid | | color | White to yellow |
| | PR104 Usage And Synthesis |
| Uses | PR-104 is a selective hypoxia-activated DNA cross-linking agent and can be used for the research of multiple tumor xenograft models. PR-104, as a nitrogen mustard pre-proagent, is converted efficiently to the more lipophilic dinitrobenzamide mustards alcohol PR-104A[1]. | | in vivo | PR-104 (0.56 mmol/kg; i.v. or i.p.; 0~2 hours) makes the plasma area under the curve. PR-104 (0.23 mmol/kg; i.p.; 100 days) shows antitumor activity[1]. | Animal Model: | CD-1nu/nu mice | | Dosage: | 0.56 mmol/kg (Pharmacokinetics Analysis) | | Administration: | I.v. or i.p. | | Result: | The plasma area under the curve.
|
| Animal Model: | CD1-Foxn1nu mice | | Dosage: | 0.23 mmol/kg | | Administration: | I.p. | | Result: | Showed antitumor activity.
|
| | References | [1] Patterson AV, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007;13(13):3922-3932. DOI:10.1158/1078-0432.CCR-07-0478 |
| | PR104 Preparation Products And Raw materials |
|